Teva to Present AUSTEDO® (deutetrabenazine) Tablets Data at the American Psychiatric Association 2018 Annual Meeting

May 2, 2018 Three abstracts evaluate the long-term safety and efficacy of AUSTEDO® (deutetrabenazine)tablets for the treatment of tardive dyskinesia in adults In addition, new health economics data assess quality of life and health burden impact among patients JERUSALEM–(BUSINESS WIRE)–May 2, 2018– Teva

Teva Presents New Long-Term Data Demonstrating Efficacy and Safety of COPAXONE® (glatiramer acetate injection) 40 mg/mL

Apr. 27, 2018 Up to 7-year efficacy, safety and tolerability results from the GALA open-label extension study presented at the 70th Annual Meeting of the AAN Over seven years, COPAXONE® 40 mg/mL provides consistent, long-term efficacy and safety JERUSALEM–(BUSINESS WIRE)–Apr. 27, 2018– Teva